|
21.
|
|
|
22.
|
|
9 p, 774.2 KB |
Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19 : A Mathematical Dynamic Model for Latin America
/
Ruiz-Patiño, Alejandro (Molecular Oncology and Biology Systems Research Group. Universidad el Bosque) ;
Arrieta, Oscar (Instituto Nacional de Cancerología (Ciutat de Mèxic). Thoracic Oncology Unit) ;
Pino, Luis E. (Fundación Santa Fe de Bogotá) ;
Rolfo, Christian (Marlene and Stewart Comprehensive Cancer Center. Experimental Therapeutics Program. School of Medicine. University of Maryland) ;
Ricaurte, Luisa (Molecular Oncology and Biology Systems Research Group. Universidad el Bosque) ;
Recondo, Gonzalo (Center for Medical Education and Clinical Research) ;
Zatarain-Barron, Zyanya Lucia (Instituto Nacional de Cancerología (Ciutat de Mèxic). Thoracic Oncology Unit) ;
Corrales, Luis. (Department of Oncology. Centro de Investigación y Manejo del Cáncer, San José, Costa Rica) ;
Martín, Claudio (Thoracic Oncology Unit. Alexander Fleming Institute) ;
Barrón, Feliciano (Instituto Nacional de Cancerología (Ciutat de Mèxic). Thoracic Oncology Unit) ;
Vargas, Carlos (Clinical and Translational Oncology Group. Clínica del Country, Bogotá) ;
Carranza, Hernán (Clinical and Translational Oncology Group. Clínica del Country, Bogotá) ;
Otero, Jorge (Clinical and Translational Oncology Group. Clínica del Country, Bogotá) ;
Rodriguez, July (Molecular Oncology and Biology Systems Research Group. Universidad el Bosque) ;
Sotelo, Carolina (Molecular Oncology and Biology Systems Research Group. Universidad el Bosque) ;
Viola, Lucia (Fundación Neumológica Colombiana) ;
Russo, Alessandro (Medical Oncology Unit. Azienda Ospedaliera Papardo) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cardona Zorrilla, Andrés Felipe (Clínica del Country (Bogotà, Colòmbia))
PURPOSE: In the midst of a global pandemic, evidence suggests that similar to other severe respiratory viral infections, patients with cancer are at higher risk of becoming infected by COVID-19 and have a poorer prognosis. [...]
2020 -  10.1200/GO.20.00156
JCO global oncology, Vol. 6 (january 2020) , p. 752-760
|
|
|
23.
|
|
13 p, 2.9 MB |
BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial : The need for a new pre-clinical treatment rationale
/
Bracht, Jillian (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Karachaliou, Niki (Hospital Universitari Sagrat Cor. Institut Oncològic Rosell) ;
Bivona, Trever (University of California. Department of Medicine) ;
Lanman, Richard B. (Guardant Health) ;
Faull, Iris (Guardant Health) ;
Nagy, Rebecca J. (Guardant Health) ;
Drozdowskyj, Ana (PIVOTAL SL) ;
Berenguer, Jordi (Institut Universitari Quirón-Dexeus. Laboratori de Biologia Molecular) ;
Fernandez-Bruno, Manuel (Hospital Universitario Sagrat Cor. Institut Oncològic Rosell) ;
Molina-Vila, Miguel Ángel (Institut Universitari Quirón-Dexeus. Laboratori de Biologia Molecular) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
BRAF V600 mutations have been found in 1-2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10. [...]
2019 - 10.3390/cancers11091381
Cancers, Vol. 11, Issue 9 (September 2019) , art. 1381
|
|
|
24.
|
|
|
25.
|
|
|
26.
|
|
161 p, 2.3 MB |
Carcinoma de pulmón no celula pequeña, con mutación de KRas : diferenciación y caracterización de subtipos, así como de los diferentes mecanismos de resistencia, para la elaboración de tratamientos dirigidos
/
Gil Moreno, María de los Llanos ;
Rosell, Rafael, dir. ;
Karachaliou, Niki, dir. ;
Feliu Frasnedo, Evarist, dir. ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Introducción: El cáncer de pulmón es el tercer tumor más frecuente y produce más de 20. 000 muertes al año en España. Pese a los avances en oncología, la quimioterapia e inmunoterapia son los únicos tratamientos para pacientes con mutación de KRAS, con resultados subóptimos. [...]
Introduction: Lung cancer is the 3rd most frequent tumor and produces more than 20,000 deaths per year in Spain. Despite recent advances in oncology chemotherapy, and inmunotherapy remains the only remedy for patients whose tumor is driven by RAS mutations, with suboptimal results. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2019.
|
|
|
27.
|
|
10 p, 1.9 MB |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
/
Codony-Servat, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cuatrecasas, Miriam ;
Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Montironi, Carla (Hospital Clínic i Provincial de Barcelona) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Marín Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Horndler, Carlos (Hospital Universitario Miguel Servet (Saragossa)) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ;
Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Reig, Oscar (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Victoria, Iván (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gaba, Lydia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Fernández-Martos, Carlos (Fundació Institut Valencià d'Oncologia) ;
Feliu, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ;
Méndez, Jose Carlos (Centro Oncológico de Galicia) ;
Méndez, Miguel (Hospital Universitario de Móstoles (Madrid)) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
Salud, Antonieta (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Rojo, Federico (Fundacion Jimenez Diaz) ;
Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ;
Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Universitat Autònoma de Barcelona
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786
|
|
|
28.
|
|
12 p, 1.4 MB |
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
/
Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Karachaliou, Niki (Instituto Oncológico Dr. Rosell, Institut Universitari Quirón-Dexeus) ;
Pilotto, Sara (Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona) ;
Codony-Servat, Jordi (Pangaea Biotech, Laboratory of Molecular Biology) ;
Cai, Xueting (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Li, Xuefei (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ;
Drozdowskyj, Ana (Pivotal, Madrid) ;
Codony Servat, Carles (Pangaea Biotech, Laboratory of Molecular Biology) ;
Yang, Jie (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Hu, Chunping (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Cardona Zorrilla, Andrés Felipe (Clinica del Country, Bogotá) ;
Lopez Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Vergnenegre, Alain (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ;
Sanchez, Jose Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Marinis, Filippo de (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Passaro, Antonio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Carcereny, Enric (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Garcia Campelo, Charo (Hospital Universitario de la Princesa (Madrid)) ;
Teixidó, Cristina (Pangaea Biotech, Laboratory of Molecular Biology) ;
Sperduti, Isabella (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Rodriguez, Sonia (Pangaea Biotech, Laboratory of Molecular Biology) ;
Lavazzi, Chiara (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Verlicchi, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Aguirre, Itziar de (Institut Germans Trias i Pujol) ;
Queralt, C (Institut Germans Trias i Pujol) ;
Wei, Jia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Estrada-Tejedor, Roger (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Puig de la Bellacasa, Raimon (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol) ;
Jacobson, Kirstine (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ;
Ditzel, Henrik J. (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ;
Santarpia, Mariacarmela (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ;
Viteri, Santiago (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Molina, Miguel Angel (Pangaea Biotech, Laboratory of Molecular Biology) ;
Zhou, Caicun (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ;
Cao, Peng (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) ;
Ma, Patrick C. (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Bivona, Trever (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. [...]
2017
Journal of the National Cancer Institute, Vol. 109 (september 2017) , p. 1-12
|
|
|
29.
|
|
|
30.
|
|
83 p, 952.5 KB |
Factors pronòstics inicials i tardans en els tumors epitelials no benignes de l'ovari : des del diagnòstic fins a les complicacions
/
Romeo, Margarita ;
Rosell, Rafael, dir. ;
Balañá, Carmen, dir. ;
Ribera, Jose-Maria, (José María) dir. ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Els tumors epitelials no benignes de l'ovari comprenen càncers i tumors borderline (BT) originats a l'ovari, trompes de Fal·lopi o peritoneu. Malgrat diferències histopatològiques i moleculars, comparteixen la via de disseminació transcelòmica, procediments diagnòstics i quirúrgics, i alguns d'ells la carcinogènesi. [...]
Non-benign epithelial ovarian tumors comprise cancers and borderline tumors (BT) that arise from the ovary, the Fallopian tubes, or the peritoneum. Despite histopathologic and molecular differences, they share a common transcelomic spreading way, diagnostic and surgical procedures and some of them are related in their carcinogenesis. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2017.
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
